$NXEN
Nexien Biopharma Inc

2024 Q2 Form 10-Q Financial Statement

#000149315224019400 Filed on May 15, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q1
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $15.95K $69.38K
YoY Change -77.01% -57.8%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $15.95K $69.38K
YoY Change -77.01% -57.8%
Operating Profit
YoY Change
Interest Expense -$37.22K -$10.48K
YoY Change 255.15% -54.53%
% of Operating Profit
Other Income/Expense, Net -$37.22K -$10.48K
YoY Change 255.18% -54.54%
Pretax Income -$53.16K -$79.85K
YoY Change -33.43% -57.4%
Income Tax
% Of Pretax Income
Net Earnings -$53.16K -$79.85K
YoY Change -33.42% -57.4%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 67.47M shares 67.47M shares 62.77M shares
Diluted Shares Outstanding 66.38M shares 62.64M shares

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.07K $54.21K
YoY Change -81.42% -61.34%
Cash & Equivalents $4.183K $10.07K $54.21K
Short-Term Investments
Other Short-Term Assets $4.200K $3.990K
YoY Change 5.26% 4.72%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $4.183K $14.27K $58.20K
YoY Change -90.3% -75.48% -59.59%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $4.183K $14.27K $58.20K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $4.183K $14.27K $58.20K
YoY Change -90.3% -75.48% -59.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $44.53K $22.41K
YoY Change 98.71% 71.07%
Accrued Expenses $53.40K $45.00K
YoY Change 18.67% 0.0%
Deferred Revenue
YoY Change
Short-Term Debt $241.6K $221.1K
YoY Change 9.29% 48.2%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $365.4K $339.6K $288.5K
YoY Change 23.82% 17.7% 39.18%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $365.4K $339.6K $288.5K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $365.4K $339.6K $288.5K
YoY Change 23.82% 17.7% 39.18%
SHAREHOLDERS EQUITY
Retained Earnings -$11.53M -$11.45M -$11.20M
YoY Change 2.12% 2.2%
Common Stock $7.047K $6.747K $6.277K
YoY Change 10.07% 7.49%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$361.2K -$325.3K -$230.3K
YoY Change
Total Liabilities & Shareholders Equity $4.183K $14.27K $58.20K
YoY Change -90.3% -75.48% -59.59%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income -$53.16K -$79.85K
YoY Change -33.42% -57.4%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$20.95K -$14.78K
YoY Change 41.75% -31.95%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 28.40K 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -20.95K -14.78K
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 28.40K 0.000
Net Change In Cash 7.450K -14.78K
YoY Change -150.41% -110.77%
FREE CASH FLOW
Cash From Operating Activities -$20.95K -$14.78K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001625288
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024Q1 NXEN Stock Payable
StockPayable
usd
CY2023Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
usd
CY2023Q4 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
usd
CY2022Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
usd
CY2022Q4 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
usd
CY2023Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
usd
NXEN Benefical Convertible Featurerelated Party Debt
BeneficalConvertibleFeaturerelatedPartyDebt
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
NXEN Debt Discount On Convertible Notes
DebtDiscountOnConvertibleNotes
usd
us-gaap Stock Issued1
StockIssued1
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
67472196 shares
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10067 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35147 usd
CY2024Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
4200 usd
CY2023Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
7980 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
14267 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
43127 usd
CY2024Q1 us-gaap Assets
Assets
14267 usd
CY2023Q2 us-gaap Assets
Assets
43127 usd
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
44526 usd
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
23643 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
339558 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
295134 usd
CY2024Q1 us-gaap Liabilities
Liabilities
339558 usd
CY2023Q2 us-gaap Liabilities
Liabilities
295134 usd
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
67472196 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
67472196 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
64022196 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
64022196 shares
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
6747 usd
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
6402 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
11115921 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
10986201 usd
CY2023Q2 NXEN Stock Payable
StockPayable
50750 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-11447959 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-11295360 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-325291 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-252007 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14267 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
43127 usd
CY2024Q1 us-gaap Professional Fees
ProfessionalFees
6665 usd
CY2023Q1 us-gaap Professional Fees
ProfessionalFees
8760 usd
us-gaap Professional Fees
ProfessionalFees
27830 usd
us-gaap Professional Fees
ProfessionalFees
30180 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9282 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
60615 usd
us-gaap Operating Expenses
OperatingExpenses
91378 usd
us-gaap Operating Expenses
OperatingExpenses
216722 usd
CY2024Q1 us-gaap Interest Expense Other
InterestExpenseOther
10238 usd
CY2023Q1 us-gaap Interest Expense Other
InterestExpenseOther
2393 usd
us-gaap Interest Expense Other
InterestExpenseOther
25280 usd
us-gaap Interest Expense Other
InterestExpenseOther
7236 usd
CY2024Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
26978 usd
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
8085 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
35941 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
44361 usd
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-37216 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-10478 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-61221 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-51597 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-53163 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-79853 usd
us-gaap Net Income Loss
NetIncomeLoss
-152599 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
28274 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-3780 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-3630 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
20883 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2012 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-53480 usd
us-gaap Net Income Loss
NetIncomeLoss
-268319 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-62691 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
20000 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
8400 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.001
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.001
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.001
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.001
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.002
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.002
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.004
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.004
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
66384284 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
66384284 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62637365 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62637365 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65353218 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65353218 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61868350 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61868350 shares
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-252007 usd
CY2023Q3 NXEN Common Stock To Be Issued To Officers
CommonStockToBeIssuedToOfficers
35000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
1125 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-74918 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-290800 usd
CY2023Q4 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
1125 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-24518 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-314193 usd
CY2024Q1 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
2200000 shares
CY2024Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
13485 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
6515 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
1265 usd
CY2024Q1 NXEN Adjustments To Additional Paid In Capital Beneficial Conversion Feature Related Party Debt
AdjustmentsToAdditionalPaidInCapitalBeneficialConversionFeatureRelatedPartyDebt
20800 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-53163 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-325291 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-117605 usd
CY2022Q3 NXEN Common Stock Issuable To Officers
CommonStockIssuableToOfficers
50750 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
1125 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-94874 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-160604 usd
CY2022Q4 NXEN Common Stock Issuable To Officers
CommonStockIssuableToOfficers
50750 usd
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
1125 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-93592 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-202321 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-202321 usd
CY2023Q1 NXEN Common Stock Issuable To Officers
CommonStockIssuableToOfficers
50750 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
1125 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-79853 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-230299 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-230299 usd
us-gaap Net Income Loss
NetIncomeLoss
-152599 usd
us-gaap Net Income Loss
NetIncomeLoss
-268319 usd
NXEN Imputed Interest On Related Party Advances
ImputedInterestOnRelatedPartyAdvances
3515 usd
NXEN Imputed Interest On Related Party Advances
ImputedInterestOnRelatedPartyAdvances
3375 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
35000 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
152250 usd
NXEN Benefical Convertible Featurerelated Party Debt
BeneficalConvertibleFeaturerelatedPartyDebt
20800 usd
NXEN Amortization Of Financing Costs And Discounts Related Party
AmortizationOfFinancingCostsAndDiscountsRelatedParty
8963 usd
NXEN Amortization Of Financing Costs And Discounts Related Party
AmortizationOfFinancingCostsAndDiscountsRelatedParty
16087 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
6178 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
28400 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-25080 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-62691 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
35147 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
116898 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10067 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
54207 usd
NXEN Debt Discount On Convertible Notes
DebtDiscountOnConvertibleNotes
20000 usd
us-gaap Stock Issued1
StockIssued1
50750 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
11447959 usd
CY2024Q1 NXEN Working Capital Deficit
WorkingCapitalDeficit
325291 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_847_eus-gaap--UseOfEstimates_zrpOIqTHOgP" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zYUShL7cMZAg">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2023Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0 usd
us-gaap Advertising Expense
AdvertisingExpense
0 usd
us-gaap Advertising Expense
AdvertisingExpense
0 usd
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p id="xdx_840_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zoYJJVW18y9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zV0EQvMnewfc">Reclassifications</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain amounts in the consolidated financial statements for prior year periods have been reclassified to conform with the current period presentation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7995000 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.26
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P2Y8M12D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7995000 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.26
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P2Y
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
5529409 shares
CY2023Q2 NXEN Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageExercisePrice
0.0429
CY2023 NXEN Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Non Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsOutstandingWeightedAverageRemainingContractualTerms
P2Y7M6D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
5529409 shares
CY2024Q1 NXEN Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageExercisePrice
0.0429
NXEN Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Non Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsOutstandingWeightedAverageRemainingContractualTerms
P1Y7M6D
NXEN Amortization Of Financing Costs And Discounts Related Party
AmortizationOfFinancingCostsAndDiscountsRelatedParty
8963 usd
NXEN Amortization Of Financing Costs And Discounts Related Party
AmortizationOfFinancingCostsAndDiscountsRelatedParty
16087 usd
CY2024Q1 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.18 pure
CY2024Q1 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
0.02
CY2024Q1 us-gaap Debt Instrument Convertible Beneficial Conversion Feature
DebtInstrumentConvertibleBeneficialConversionFeature
20800 usd
CY2024Q1 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
0.02

Files In Submission

Name View Source Status
0001493152-24-019400-index-headers.html Edgar Link pending
0001493152-24-019400-index.html Edgar Link pending
0001493152-24-019400.txt Edgar Link pending
0001493152-24-019400-xbrl.zip Edgar Link pending
ex10-11.htm Edgar Link pending
ex10-11_001.jpg Edgar Link pending
ex10-11_002.jpg Edgar Link pending
ex10-11_003.jpg Edgar Link pending
ex10-11_004.jpg Edgar Link pending
ex10-11_005.jpg Edgar Link pending
ex10-11_006.jpg Edgar Link pending
ex10-11_007.jpg Edgar Link pending
ex10-11_008.jpg Edgar Link pending
ex10-11_009.jpg Edgar Link pending
ex10-11_010.jpg Edgar Link pending
ex10-11_011.jpg Edgar Link pending
ex10-11_012.jpg Edgar Link pending
ex10-11_013.jpg Edgar Link pending
ex10-11_014.jpg Edgar Link pending
ex10-11_015.jpg Edgar Link pending
ex10-11_016.jpg Edgar Link pending
ex10-11_017.jpg Edgar Link pending
ex10-11_018.jpg Edgar Link pending
ex10-11_019.jpg Edgar Link pending
ex10-11_020.jpg Edgar Link pending
ex10-11_021.jpg Edgar Link pending
ex10-11_022.jpg Edgar Link pending
ex10-11_023.jpg Edgar Link pending
ex10-11_024.jpg Edgar Link pending
ex10-11_025.jpg Edgar Link pending
ex10-11_026.jpg Edgar Link pending
ex10-11_027.jpg Edgar Link pending
ex10-12.htm Edgar Link pending
ex10-12_001.jpg Edgar Link pending
ex10-12_002.jpg Edgar Link pending
ex10-12_003.jpg Edgar Link pending
ex10-12_004.jpg Edgar Link pending
ex10-12_005.jpg Edgar Link pending
ex10-12_006.jpg Edgar Link pending
ex10-12_007.jpg Edgar Link pending
ex10-12_008.jpg Edgar Link pending
ex10-12_009.jpg Edgar Link pending
ex10-12_010.jpg Edgar Link pending
ex10-12_011.jpg Edgar Link pending
ex10-12_012.jpg Edgar Link pending
ex10-12_013.jpg Edgar Link pending
ex10-12_014.jpg Edgar Link pending
ex10-12_015.jpg Edgar Link pending
ex10-12_016.jpg Edgar Link pending
ex10-12_017.jpg Edgar Link pending
ex10-12_018.jpg Edgar Link pending
ex10-12_019.jpg Edgar Link pending
ex10-12_020.jpg Edgar Link pending
ex10-13.htm Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
nxen-20240331.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
nxen-20240331_cal.xml Edgar Link unprocessable
nxen-20240331_def.xml Edgar Link unprocessable
nxen-20240331_lab.xml Edgar Link unprocessable
nxen-20240331_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable